CoChat

Acarbose treatment affects the serum levels of inflammatory cytokines and the gut content of bifidobacteria in Chinese patients with type 2 diabetes mellitus: 阿卡波糖对中国2型糖尿病患者炎症因子及粪便双歧杆菌水平的作用

Su, Benli, Liu, Haixia, Li, Jing, Sunli, Yongjuan, Liu, Ben, Liu, Dandan, Zhang, Ping, Meng, Xiuxiang · 2015 · Journal of Diabetes
Cited by 137

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Abstract

Background: The effects of acarbose add‐on therapy on gut microbiota and inflammatory cytokines were investigated in C hinese patients with type 2 diabetes mellitus (DM). Methods: Ninety‐five DM patients were randomly allocated to two groups: 59 to Group A who received antidiabetic treatment that included acarbose 150 mg/day, and 36 to Group B who received similar treatment to Group A but without acarbose. Forty‐five healthy volunteers were selected as a control group. Serum concentrations of inflammatory cytokines were determined by ELISA, and the contents of 16S rDNA of gut bacteria were determined by real‐time quantitative polymerase chain reaction. General linear analysis for repeated measurements was used to analyze trend differences between the two diabetic groups. Results: After 4 weeks of antidiabetic treatment, the gut contents of B ifidobacterium longum and E nterococcus faecalis were significantly increased in both diabetes groups. The increase of B ifidobacterium longum (P = 0.004) and the decrease of lipopolysaccharides (LPS) (P < 0.001) and prothrombin activator inhibitor‐1 (P = 0.003) were more significant in Group A. Decreases of monocyte chemoattractant protein‐1 and LPS were more significant in patients whose HbA1c decrease was ≥1%, but there were no significant differences in the changes of other cytokines and gut bacteria between patients with HbA1c <7% and ≥7%. Pearson correlation analysis showed that changes of E nterococcus faecalis were negatively correlated with LPS, while multiple linear regression analysis showed a positive correlation of B ifidobacterium longum with acarbose treatment and the high‐density lipoprotein cholesterol concentration. Conclusions: Acarbose treatment can increase the content of gut B ifidobacterium longum in type 2 diabetes mellitus patients and decrease some inflammatory cytokines independently of its antihyperglycemic effects.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/1753-0407.12232

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Cited by

Metadata

Authors
Su, B., Liu, H., Li, J., Sunli, Y., Liu, B., Liu, D., Zhang, P., & Meng, X.
Venue
Journal of Diabetes
Publisher
Wiley
Published
2015-01-15
Volume
7
Issue
5
Pages
729-739
ISSN
  • 1753-0393 (ISSN-L)
  • 1753-0407
OpenAlex
W1928552205
Cited by
137
References
15
FWCI
1.70
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.